Cerebrolysin vs Dihexa
Neurotrophic Peptide Mixture · Angiotensin IV Analog
Here is how these two compounds compare, based on published research, not marketing claims.
Cerebrolysin
A porcine brain peptide preparation with international clinical trials across stroke, traumatic brain injury, and dementia.
Dihexa
A synthetic angiotensin IV analog promoting synaptogenesis in laboratory studies; zero published human clinical data.
Cerebrolysin
658 studies
52 human trials
Not FDA-Approved
Dihexa
11 studies
0 human trials
Not FDA-Approved
What it does
Cerebrolysin
Delivers brain-repair signals into tissue that the bloodstream normally cannot reach. Made of short peptide fragments derived from pig brain tissue, small enough to cross the blood-brain barrier.
Dihexa
Promotes the formation of new synaptic connections in the brain through hepatocyte growth factor (HGF) signaling. Reported in laboratory studies as a potent driver of synaptogenesis, the process by which brain cells form new communication pathways.
How it works
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids produced by enzymatic breakdown of purified porcine brain proteins. The peptide fragments are small enough to cross the blood-brain barrier and mimic the activity of naturally occurring neurotrophic factors (BDNF, NGF, CNTF). Once in brain tissue, the fragments promote neuronal survival, stimulate synaptic plasticity, and support axonal growth and repair. The multi-target mechanism is the defining pharmacological feature: rather than hitting one receptor, cerebrolysin modulates several neuroprotective and neurorestorative pathways simultaneously.
Dihexa
Dihexa is a synthetic analog of angiotensin IV developed at Washington State University. It binds to and activates the hepatocyte growth factor (HGF) receptor (also called MET), which drives synaptogenesis and dendritic spine formation in brain tissue. In laboratory studies, the Harding research group reported that dihexa promoted synaptic connections at concentrations far lower than BDNF in cell culture models. The mechanism operates through MET receptor signaling rather than the conventional neurotrophin pathway, representing a pharmacologically distinct approach to synaptic plasticity.
How often
Cerebrolysin
Intravenous or intramuscular injection in clinical protocols across 40+ countries where cerebrolysin is approved. Published trials use multi-week treatment courses. Cerebrolysin is not FDA-approved in the United States; clinical availability in the U.S. does not exist through standard channels.
Dihexa
No standardized dosing protocol exists. Dihexa has been studied in animal models (rats) for cognitive effects. No human clinical trials have been published. The compound is available in research peptide markets but has no regulatory status in any country.
How strong
Cerebrolysin
Approved in more than 40 countries for stroke recovery, traumatic brain injury, and various forms of dementia. Large-scale clinical trials in stroke rehabilitation (CASTA, CARS) showed functional recovery benefits. The evidence base includes over 200 published studies with more than 50 human clinical trials. The strongest data is in acute ischemic stroke recovery and post-TBI rehabilitation, where multiple independent research groups have replicated findings.
Dihexa
The in vitro synaptogenesis data from the Harding lab is compelling at the mechanistic level. Animal studies showed improved cognitive performance in aged rats. The HGF/MET pathway approach is pharmacologically distinct from traditional nootropics. However, zero published human data exists. The gap between laboratory potency and clinical validation is the defining feature of this compound's evidence profile.
Main tradeoff
Cerebrolysin
Internationally approved with decades of clinical use in stroke and TBI rehabilitation across more than 40 countries. Not FDA-approved in the United States; the specific U.S. trial package the FDA requires was never completed despite international clinical evidence. The 2013 Cochrane review found the evidence insufficient to draw definitive conclusions about efficacy in dementia, though subsequent trials have added data. Injectable-only delivery limits accessibility. As a porcine-derived biological product, batch-to-batch consistency and standardization are more complex than for synthetic peptides.
Dihexa
The most potent synaptogenesis enhancer in laboratory studies has zero published human clinical data. Dihexa is widely sold as a research peptide based on a small body of academic research from a single laboratory. No independent replication of the core findings has been published. No human safety data exists. The compound has not entered any clinical trial program. The distance between the laboratory data and clinical use is the largest of any widely-sold nootropic peptide.
Best for
Cerebrolysin
- Research interest in neuropeptide-based neuroprotection and neuroregeneration
- Research focused on stroke recovery, traumatic brain injury rehabilitation, or dementia where international clinical trial data applies
- Research comparing multi-target neuropeptide preparations versus single-target nootropic compounds
Dihexa
- Research on HGF/MET receptor signaling as a synaptogenesis pathway distinct from BDNF
- Research on angiotensin IV analogs and their cognitive effects in animal models
- Research evaluating the gap between in vitro potency and clinical translation in nootropic development
How to choose
A good fit for Cerebrolysin
- Research on neuroprotection with established clinical trial evidence
- Research contexts where international regulatory approval and safety data carry weight
- Research on stroke recovery, traumatic brain injury, or Alzheimer's disease
A good fit for Dihexa
- Research on HGF/MET-driven synaptogenesis as a mechanistic pathway
- Research on preclinical-to-clinical translation gaps in neuroscience
- Research on angiotensin IV analogs and their cognitive effects in animal models
Consider both across time
Cerebrolysin and Dihexa represent the full spectrum from clinical validation to preclinical promise. Cerebrolysin has decades of international clinical use with multiple RCTs. Dihexa has compelling laboratory data from the Harding lab with no human validation. For clinical neuroprotection research, Cerebrolysin is the evidence-backed choice. For mechanistic synaptogenesis research, Dihexa is the relevant compound. The comparison illustrates why preclinical potency alone does not constitute clinical evidence.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Blood-Brain Barrier Crossing
- Blood-Brain Barrier Crossing enables Neurotrophic Factor Mimicry
- Neurotrophic Factor Mimicry connects to Neuronal Survival
- Neurotrophic Factor Mimicry connects to Synaptic Plasticity
- Neurotrophic Factor Mimicry connects to Axonal Growth and Repair
- Neuronal Survival connects to Cognitive and Functional Recovery; Synaptic Plasticity connects to Cognitive and Functional Recovery; Axonal Growth and Repair connects to Cognitive and Functional Recovery
- HGF Receptor Binding
- HGF Receptor Binding activates MET Signaling Activation
- MET Signaling Activation drives Synaptogenesis
- Synaptogenesis connects to Dendritic Spine Formation
- Synaptic Density Increase connects to Cognitive Enhancement
- Dendritic Spine Formation connects to Synaptic Density Increase
Cerebrolysin's peptide fragments cross the blood-brain barrier to mimic neurotrophic factors that promote neuronal survival and synaptic plasticity.
Dihexa activates the HGF/MET receptor pathway to drive synaptogenesis and dendritic spine formation in brain tissue.
Research Evidence
Cerebrolysin has substantially more clinical evidence: multiple international randomized controlled trials across stroke (CASTA, CERE-STROKE), traumatic brain injury, and Alzheimer's disease. Dihexa has a small body of preclinical research from the Harding laboratory with animal cognitive studies and in vitro synaptogenesis data. The evidence gap is the widest of any comparison in the Cognitive category.
- 1.
For evidence-based neuroprotection, cerebrolysin has extensive clinical validation.
- 2.
For theoretical synaptogenesis research, dihexa's animal data is scientifically interesting.
- 3.
For any clinical decision, cerebrolysin is the only option with human experience.
- 4.
Dihexa represents potential. Cerebrolysin represents evidence.
Key Limitations
- •This comparison is inherently asymmetric, one is established, the other is preclinical.
- •Dihexa's extraordinary potency claims come from a single research group.
- •Animal cognitive models do not reliably predict human cognitive outcomes.
- •Cerebrolysin's multi-component nature and dihexa's single-mechanism focus make different kinds of comparison difficult.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Cerebrolysin
"Cerebrolysin is used in hospitals across Europe and Asia"
Supported by evidence
"Cerebrolysin improved my cognitive function after brain injury"
Plausible (clinical data exists)
Dihexa
"Dihexa is millions of times more potent than BDNF"
Technically accurate but misleading
"Dihexa is the strongest nootropic available"
Insufficient evidence
"I'm worried about dihexa and cancer risk"
Legitimate concern
Safety Comparison
Cerebrolysin has extensive clinical safety data from international trials and decades of clinical use in multiple countries. The most common adverse effects are injection site reactions and mild headache. Dihexa has no published human safety data. The HGF/MET pathway activated by Dihexa is involved in cell growth and proliferation, raising theoretical safety questions that have not been addressed in any human study.
Cerebrolysin
Approved in 40+ countries. Decades of clinical safety data. IV and IM administration. Generally well-tolerated.
Dihexa
No human safety data. Very potent compound. HGF pathway involvement raises theoretical growth factor concerns.
What the Research Suggests
Cerebrolysin is the evidence-based option. Dihexa is the exciting speculation. Many exciting speculations in neuroscience have failed to translate to humans.